• AdAlta, Oribiotech and Cell Therapies sign MoU to bring Oribiotech's automated cell therapy manufacturing platform, IRO, to Australia and Asia Pacific
• IRO aims to address key CAR-T challenges: high cost, slow production, and inconsistent results
• Next-generation automation targets: 10-50x higher throughput, shorter manufacturing times, 30-50% potential cost savings

AdAlta Limited (ASX:1AD), Oribiotech Ltd ('Ori') and Cell Therapies Pty Ltd ('CTPL') have signed a Memorandum of Understanding (MoU) to bring Ori's next-generation automated cell therapy manufacturing platform, IRO®, to AdAlta's pipeline and more broadly to cell therapy researchers and developers in Australia and Asia Pacific. CAR-T therapies are transforming cancer treatment, but making them at scale is complex and costly. Current manufacturing platforms present challenges including cost, throughput and scalability, which are major hurdles to making these life-saving treatments widely available. The IRO platform aims to change that by automating key steps, improving consistency, and reducing costs. IRO targets 10-50x higher throughput, shorter manufacturing times, and 30-50% potential cost savings. This collaboration is an important step toward solving one of the biggest challenges in cell therapy, manufacturing at scale, while positioning the AdAlta group as a leader in 'East to West' globalisation of cellular immunotherapies and CTPL as the leading cell therapy contract manufacturer in the Asia-Pacific region.

This collaboration is an important step toward solving one of the biggest challenges in cell therapy, manufacturing at scale, while positioning the AdAlta group as a leader in 'East to West' globalisation of cellular immunotherapies and CTPL as the leading cell therapy contract manufacturer in the Asia-Pacific region.